| pubmed-article:9041204 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9041204 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:9041204 | lifeskim:mentions | umls-concept:C0034802 | lld:lifeskim |
| pubmed-article:9041204 | lifeskim:mentions | umls-concept:C1512505 | lld:lifeskim |
| pubmed-article:9041204 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:9041204 | lifeskim:mentions | umls-concept:C1514485 | lld:lifeskim |
| pubmed-article:9041204 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9041204 | pubmed:dateCreated | 1997-3-28 | lld:pubmed |
| pubmed-article:9041204 | pubmed:abstractText | This report describes the isolation and characterization of a new human breast cancer cell line, SUM-102PT, obtained from a minimally invasive human breast carcinoma. SUM-102PT cells have a near diploid karyotype, and early-passage cells had minor chromosomal abnormalities including a 5, 12 and a 6, 16 reciprocal translocation. The cells were isolated and have been continually cultured in three defined media, one of which contains exogenous epidermal growth factor (EGF). SUM-102PT cells have also been carried in an EGF-free medium supplemented with progesterone. All SUM-102PT cells require EGF receptor (EGFR) activation for continuous growth, because incubation of the cells with EGFR-neutralizing antibodies or with EGFR kinase inhibitors blocks growth of these cells. Southern analysis indicates that the EGFR gene is not amplified in these cells; however, these cells express high levels of EGFR mRNA. Thus, SUM-102PT is representative of a class of human breast cancers characterized by high level EGFR expression in the absence of gene amplification. SUM-102PT cells cultured in EGF-free, progesterone-containing medium express high levels of constitutively active EGFR. Conditioned medium from SUM-102PT cells contains an EGF-like mitogen that binds to a heparin-agarose affinity matrix with high affinity. Northern analysis for various EGF family members indicates that SUM-102PT cells synthesize heparin binding (HB)-EGF mRNA. HB-EGF protein is detectable on the surface of these cells by immunohistochemistry, and SUM-102PT cells are killed by diphtheria toxin, which acts by binding to HB-EGF. Furthermore, HB-EGF antibodies partially neutralize the mitogenic activity of the conditioned medium. Thus, EGFR activation in SUM-102PT cells is mediated, at least in part, by autocrine/juxtacrine stimulation by HB-EGF. SUM-102PT cells also express constitutively active STAT-3 homodimers. Constitutively tyrosine-phosphorylated STAT-3 homodimers were also detected in another breast cancer cell line, MDA468, which has an EGFR amplification and also has constitutive EGFR activity. Thus, SUM-102PT is a new human breast cancer cell line that expresses activated EGFR as a result of an autocrine/juxtacrine interaction with HB-EGF which, in turn, results in activation of STAT-3. | lld:pubmed |
| pubmed-article:9041204 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9041204 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9041204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9041204 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9041204 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:9041204 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:9041204 | pubmed:author | pubmed-author:YuC LCL | lld:pubmed |
| pubmed-article:9041204 | pubmed:author | pubmed-author:SartorC ICI | lld:pubmed |
| pubmed-article:9041204 | pubmed:author | pubmed-author:JoveRR | lld:pubmed |
| pubmed-article:9041204 | pubmed:author | pubmed-author:EthierS PSP | lld:pubmed |
| pubmed-article:9041204 | pubmed:author | pubmed-author:DziubinskiM... | lld:pubmed |
| pubmed-article:9041204 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9041204 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:9041204 | pubmed:volume | 57 | lld:pubmed |
| pubmed-article:9041204 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9041204 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9041204 | pubmed:pagination | 978-87 | lld:pubmed |
| pubmed-article:9041204 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:meshHeading | pubmed-meshheading:9041204-... | lld:pubmed |
| pubmed-article:9041204 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9041204 | pubmed:articleTitle | Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. | lld:pubmed |
| pubmed-article:9041204 | pubmed:affiliation | Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor 48109-0582, USA. | lld:pubmed |
| pubmed-article:9041204 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9041204 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9041204 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:9041204 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9041204 | lld:pubmed |
